The Effects of Oral Dehydroepiandrosterone on Endocrine-Metabolic Parameters in Postmenopausal Women

Journal of Clinical Endocrinology and Metabolism

Volumn 71, Issue 3, 1990, Pages 696-704

  Mortola, J F ^a   Yen, S S C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PRASTERONE; RADIOISOTOPE; SEX HORMONE BINDING GLOBULIN;

ADULT; ARTICLE; FEMALE; HUMAN EXPERIMENT; INSULIN RESISTANCE; MENOPAUSE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADRENAL GLANDS; AGED; AGING; ANDROGENS; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HUMAN; INSULIN; LIPIDS; MENOPAUSE; MIDDLE AGE; OBESITY; PRASTERONE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THYROID HORMONES;

EID: 0025046185     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-71-3-696     Document Type: Article

References (63)

1. dePeretti E, Forest M. Unconjugated DHEA plasma levels in normal subjects from birth to adolescence in humans. J Clin Endocrinol Metab. 1976;43:982-90.
2. Parker LN, Odell WD. Control of adrenal androgen secretion. Endocr Rev. 1980;4:392-410.
3. Hopper BR, Yen SSC. Circulating concentrations of déhydroépiandrostérone and dehydroepiandrosterone sulfate during puberty. J Clin Endocrinol Metab. 1975;40:458-61.
4. Orienteich L, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentration throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-5.
5. Schiebinger RJ, Albertson BD, Cassorla FG, Bowyer DW, Cellhoed GW, Cutler GB. The development changes in plasma adrenal androgens during infancy and adrenarche are associated with changing activities of adrenal microsomal 17-hydroxylase and 17, 20-desmolase. J Clin Invest. 1982;67:1177-82.
6. Byrne GC, Perry YS, Winter JSD. Kinetic analysis of adrenal 3β-hydroxysteroid dehydrogenase activity during human development. J Clin Endocrinol Metab. 1985;60:934-9.
7. Couch RM, Muller J, Winter JSD. Regulation of the activities of 17-hydroxylase and 17, 20-desmolase in the human adrenal cortex: kinetic analysis and inhibition by endogenous steroids. J Clin Endocrinol Metab. 1986;63:613-8.
8. Liu CH, Laughlin GA, Fischer UG, Yen SSC. Marked attenuation of the circadian pulsatile secretion of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17, 20-desmolase enzymatic activity. J Clin Endocrinol Metab. In Press.
9. Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone in diabetic mice. Diabetes. 1982;31:830-3.
10. Coleman DL. Therapeutic effects of dehydroepiandrosterone (DHEA) and its metabolites in obese hyperglycemic mutant mice. Prog Clin Biol Res. 1982;265:161-5.
11. Coleman DL, Schwizer RW, Leiter EH. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and aged normal mice. Diabetes. 1984;33:26-33.
12. vy/a mice by dehydroepiandrosterone. Lipids. 1977;12:409-13.
13. Ben-David M, Dikstein S, Bismuth G, Sulman PG. Antihypercho-lesterolemic effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med. 1967;125:1136-40.
14. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hy-percholesterolemic New Zealand White rabbit with aortic intimai injury. J Clin Invest. 1988;82:712-20.
15. Lucas JA, Ahmed SA, Casey LM, MacDonald PC. Prevention autoantibody formation and prolonged survival in New Zealand Black/New Zealand White Fi mice fed dehydroepiandrosterone. J Clin Invest. 1985;75:2091-3.
16. Tannen RH, Schwartz AG. Reduced weight gain and delay of Coombs positive hemolytic anemia in NZB mice treated with dehydroepiandrosterone (DHEA). Fed Proc. 1982;42:463-6.
17. Blauer KI, Rogers WM, Benton EW. Dehydroepiandrosterone antagonizes the suppressive effects of glucocorticoids on lymphocyte proliferation [Abstract 25]. Proc of the 71st Annual Meet of The Endocrine Soc. 1989.
18. Rogers WM, Blauer KL, Bernton W. Dehydroepiandrosterone protection against dexamethasone induced thymic involution: flow cytometric and mechanistic studies [Abstract 28]. Proc of the 71st Annual Meet of The Endocrine Soc. 1989.
19. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol. 1988;26:301-4.
20. vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res. 1979;39:1129-31.
21. Shantz LM, Talalav P, Gordon GB. Mechanism of inhibition of growth of 3T3-L1 fibroblasts and their differentiation to adipocytes by dehydroepiandrosterone and related steroids: role of glucose-6-phosphate dehydrogenase. Proc Natl Acad Sci USA. 1989;86:3852-6.
22. Feo F, Pirisi L, Pscale R, et al. Modulatory mechanisms of chemical carcinogenesis: the role of the NADPH pool in the benzo(a)pyrene activation. Toxicol Pathol. 1984;12:261-8.
23. Nyce JW, Magee PN, Hard GC, Schwartz AG. Inhibition of 1, 2 dimethylhydrazine induced colon tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis (Lond). 1984;5:57-62.
24. Barrett-Conner E, Khaw K-T, Yen SSC. A prospective study of dehydroepiandrosterone-sulfate, mortality and cardiovascular disease. N Engl J Med. 1986;315:1519-24.
25. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid secretion excretion and subsequent breast cancer. Lancet. 1975;2:395-8.
26. Thoman ML, Weigle WO. The cellular and subcellular bases of immunosenescence. Adv Immunol. 1989;46:221-40.
27. Drucker MD, Blumberg JM, Gandy HM, David RR, Verde AL. Biologic activity of dehydroepiandrosterone sulfate in man. J Clin Endocrinol Metab. 1972;35:48-54.
28. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 1988;66:57-61.
29. Mattson L-A, Cullberg G, Tangkeo P, Zador G, Samsioe G. Administration of dehydroepiandrosterone enanthrate to oophorec-tomized women-effects on sex hormones and lipid metabolism. Maturitas. 1980;2:301-9.
30. Metropolitan Life Insurance Co. Height and weight tables. Metropolitan Life Foundation Stat Bull. 1980;67:2-64.
31. Behnke AR, Feen BG, Welham WC. The specific gravity of healthy men. JAMA. 1942;118:495-503.
32. Siri WE. Body composition from fluid spaces and density. Analysis of methods. In: Brozek J, Henschel A, eds. Proceedings of the Conference January 22-23, 1959, National Academy of Sciences. Washington DC: National Research Council; 1961;223.
33. Anderson DC, Hopper BR, Lasley BL, Yen SSC. A simple method for assay of eight steroids in small volumes of plasma. Steroids. 1976;28:179-96.
34. Yen SSC, Llerena O, Little B, Pearson OH. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab. 1968;28:1763-7.
35. Rosner W. A simplified method for the quantitative determination of testosterone-estrogen binding globulin activity. J Clin Endocrinol Metab. 1972;34:983-8.
36. Kuzuya H, Blix PM, Horowitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin treated diabetes. Diabetes. 1977;26:22-9.
37. Lowe ML, Stella AF, Mosher BS, Gin JB, Demitridu JA. Microflu-rometry of G6PD and 6-phosphogluconate dehydrogenase in red cells. Clin Chem 1972;18:440-5.
38. Segal P, Bachorik P, Rifkind B, Levy R. Lipids and dyslipoprotei-nemia. In: Henry RB, ed. Clinical diagnosis and management by laboratory methods. Philadelphia: Saunders; 1984;186-93.
39. Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of conversion to testosterone. J Clin Invest. 1966;44:301-66.
40. Haning Jr RV, Chabot M, Flood CA, Hackett R, Longcope C. Metabolic clearance rate (MCR) of dehydroepiandrosterone sulfate (DS), its metabolism to androstenedione, testosterone and dihydrotestosterone, and the effect of increased plasma DS concentration on DS MCR in normal women. J Clin Endocrinol Metab. 1989;69:1047-52.
41. Wathen NC, Perry LA, Rubenstein E, Chard T. A relationship between sex-hormone binding globulin and dehydroepiandrosterone sulfate in normally menstruating females. Gynaecol Endocrinol. 1987;1:47-52.
42. Stefanick ML, Williams PT, Krauss RM, Terry RB, Vranizan KM, Wood PD. Relationships of plasma estradiol, testosterone and sex hormone-binding globulin with lipoproteins, apolipoproteins, and high density lipoprotein subfractions in man. J Clin Endocrinol Metab. 1987;64:723-9.
43. Semmens J, Rouse I, Beilin LJ, Masarei JRL. Relationship of HDL-cholesterol to testosterone, estradiol and sex-hormone binding globulin levels in men and women. Metabolism. 1983;32:428-32.
44. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8:1-28.
45. Federman DD, Robbins J, Roll JE. Effects of methyl testosterone on thyroid function, thyroxine and thyroxine binding protein. J Clin Invest. 1958;37:2103-7.
46. Barbosa J, Seal US, Doe RP. Effects of anabolic steroids on hormone binding proteins, serum cortisol and serum nonprotein bound cortisol. J Clin Endocrinol Metab. 1971;32:232-40.
47. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose tolerance. J Clin Invest. 1985;75:809-17.
48. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in power lifters injecting anabolic steroids. J Clin Endo crinol Metab. 1987;64:960-3.
49. Shoupe D, Lobo RA. The influence of androgens on insulin resistance. Fertil Steril. 1984;41:385-8.
50. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandro-genism with hyperinsulinism in polycystic ovary disease. J Clin Endocrinol Metab. 1980;50:113-6.
51. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non-obese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356-9.
52. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrenemic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab. 1987;65:449-507.
53. Smith S, Ravnikar VA, Barbiéri RL. Androgen and insulin response to an oral glucose tolerance test in hyperandrogenemic women. Fertil Steril. 1987;48:72-7.
54. Schriocik ED, Buffington CK, Hubert GD, et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 1988;66:1329-31.
55. Nestler JE, Usiskin KS, Barlascini CO, Welty DF, Clore JN, Blackard WG. Suppression of serum dehydroepiandrosterone sulfate levels by insulin. An evaluation of possible mechanisms. J Clin Endocrinol Metab. 1989;69:1040-6.
56. Nestler JE, Clore JN, Strauss II JF, Blackard WG. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in women with hyperandrogenism, insulin resistance and acanthosis nigricans. J Clin Endocrinol Metab. 1987;64:180-4.
57. Diamond MP, Grainger D, Gill AL, Zych K, Knab G, DeFronco RA. Exogenous and endogenous elevations in circulating insulin levels are associated with acute reduction in levels of dehydroepiandrosterone sulfate (DHEAS), but not androstenedione (A), testosterone (T), or free testosterone (FT) [Abstract 424]. Proc of the 36th Annual Meet of the Soc for Gynecol Invest. 1989;293.
58. Whittaker PG, Morgan MRA, Cameron EHD. Serum equilin, estrone, and estradiol levels in postmenopausal women receiving conjugated equine estrogens (“Premarin”). Lancet. 1:14-6.
59. Yen SS, Martin PL, Burnier AM, Czekala NM, Greancy Jr MO, Callantine MR. Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17-beta-estradiol in postmenopausal women. J Clin Endocrinol Metab. 1975;40:518-21.
60. Laufer I, De Fazio J, Lu J, et al. Estrogen replacement by transdermal estradiol administration. Am J Obstet Gynecol. 1983;146:533-40.
61. Spellacy WN, Buhi WC, Birk SA. The effects of estrogen on carbohydrate metabolism: glucose insulin and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol. 1972;114:378-42.
62. Thom M, Chakravarti S, Oram DH, Studd JWW. Effect of hormone replacement on glucose tolerance in post-menopausal women. Br J Obstet Gynaecol. 1976;84:776-83.
63. Lind T, Cameron EC, Hunter WM, et al. A prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol. 1979;86:1-29.